[go: up one dir, main page]

AU2001272257A1 - Hcv mosaic antigen composition - Google Patents

Hcv mosaic antigen composition

Info

Publication number
AU2001272257A1
AU2001272257A1 AU2001272257A AU7225701A AU2001272257A1 AU 2001272257 A1 AU2001272257 A1 AU 2001272257A1 AU 2001272257 A AU2001272257 A AU 2001272257A AU 7225701 A AU7225701 A AU 7225701A AU 2001272257 A1 AU2001272257 A1 AU 2001272257A1
Authority
AU
Australia
Prior art keywords
hcv
antigen composition
mosaic antigen
diagnostic
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001272257A
Inventor
Hermes K.W. Chan
Richard Theolis Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medmira Inc
Original Assignee
Medmira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medmira Inc filed Critical Medmira Inc
Publication of AU2001272257A1 publication Critical patent/AU2001272257A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A highly immunoreactive mosaic antigen composition comprising a plurality of antigenic peptides derived from the core region of a polyprotein encoded by the hepatitis C virus (HCV) genome is provided for the purpose of detecting anti-HCV antibodies. The mosaic antigen composition essentially comprises a combination of six different antigenic peptides, ranging in length from 12 to 19 amino acid residues, which are individually immobilized through covalent linkage to a carrier component at their terminal end. The unique combination of HCV core peptides provided as a mosaic antigen composition having the three-dimensional configuration described herein results in higher specificity and sensitivity for detection of human antibodies specific to HCV in rapid HCV diagnostic applications. An <i>in vitro</i> diagnostic method for detecting anti-HCV antibodies in a test sample and a diagnostic test kit are also provided which utilize the mosaic antigen composition as an immunoreagent.
AU2001272257A 2000-07-07 2001-07-06 Hcv mosaic antigen composition Abandoned AU2001272257A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2311022 2000-07-07
CA2311022 2000-07-07
PCT/CA2001/000988 WO2002004484A2 (en) 2000-07-07 2001-07-06 Hcv mosaic antigen composition

Publications (1)

Publication Number Publication Date
AU2001272257A1 true AU2001272257A1 (en) 2002-01-21

Family

ID=4166420

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001272257A Abandoned AU2001272257A1 (en) 2000-07-07 2001-07-06 Hcv mosaic antigen composition

Country Status (6)

Country Link
EP (1) EP1328811B1 (en)
AT (1) ATE303597T1 (en)
AU (1) AU2001272257A1 (en)
DE (1) DE60113139T2 (en)
ES (1) ES2248357T3 (en)
WO (1) WO2002004484A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1357127A1 (en) 2002-04-10 2003-10-29 Immusystems GmbH Hepatitis c virus epitopes specific for cd4+ t-cell lymphocytes
US20040106526A1 (en) * 2002-12-03 2004-06-03 Baxter David Roderick Method for marking liquid hydrocarbons
CN102659922B (en) * 2003-09-22 2013-11-06 株式会社绿多肽 Peptide Derived From Hepatitis C Virus
US8475735B2 (en) 2004-11-01 2013-07-02 Uma Mahesh Babu Disposable immunodiagnostic test system
CN101300355A (en) * 2005-10-13 2008-11-05 威瑞克斯医药公司 Chimeric antigen comprising hepatitis C virus polypeptide and Fc fragment for eliciting an immune response
JP2009018990A (en) * 2005-10-25 2009-01-29 Univ Kurume Hepatitis C virus-derived peptide
EP1952158A2 (en) 2005-11-12 2008-08-06 Platform Diagnostics Limited Agglutination assay
CA2580589C (en) 2006-12-19 2016-08-09 Fio Corporation Microfluidic detection system
EP1978365B1 (en) 2007-03-16 2010-08-25 Sysmex Corporation Reagent kit and method for measuring HCV antibody
JP4975600B2 (en) * 2007-03-16 2012-07-11 シスメックス株式会社 Reagent kit for HCV antibody measurement and HCV antibody measurement method
JP4975601B2 (en) * 2007-03-16 2012-07-11 シスメックス株式会社 Reagent kit for HCV antibody measurement and HCV antibody measurement method
CA2702367C (en) 2007-10-12 2012-08-21 Fio Corporation Flow focusing method and system for forming concentrated volumes of microbeads, and microbeads formed further thereto
CA2729023C (en) 2008-06-25 2013-02-26 Fio Corporation Bio-threat alert system
MX2011002235A (en) 2008-08-29 2011-04-05 Fio Corp A single-use handheld diagnostic test device, and an associated system and method for testing biological and environmental test samples.
CN102348986B (en) 2009-01-13 2015-05-06 Fio公司 Handheld diagnostic test device and method for use in combination with electronic devices and test cartridges in rapid diagnostic tests
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
CN118818064A (en) * 2024-08-23 2024-10-22 深圳上泰生物工程有限公司 A kind of anti-phospholipase A2 receptor antibody detection kit

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE206717T1 (en) * 1990-11-03 2001-10-15 Dade Behring Marburg Gmbh HCV-SPECIFIC PEPTIDES, AGENTS THEREOF AND USE THEREOF
SG47062A1 (en) * 1990-12-14 1998-03-20 Innogenetics Nv Synthetic antigens for the detection of antibodies to hepatitis virus
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)

Also Published As

Publication number Publication date
DE60113139T2 (en) 2006-06-22
WO2002004484A2 (en) 2002-01-17
EP1328811A2 (en) 2003-07-23
EP1328811B1 (en) 2005-08-31
WO2002004484A3 (en) 2002-03-28
DE60113139D1 (en) 2005-10-06
ATE303597T1 (en) 2005-09-15
ES2248357T3 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
AU2001272257A1 (en) Hcv mosaic antigen composition
FI112438B (en) A DNA molecule and a method for the detection of antibodies against hepatitis C virus
US7402315B2 (en) Hepatitis-C virus type 4, 5 and 6
US6217872B1 (en) Non-A, non-B hepatitis virus genomic cDNA and antigen polypeptide
RU2001101869A (en) HCV Shell Protein Particles: Vaccination Use
CA2184890A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis c virus
EP0542970A1 (en) Nucleotide and peptide sequences of an isolate of the hepatitis c virus, diagnostic and therapeutic applications thereof
CA2483945A1 (en) Method for simultaneously detecting an antigen and an antibody of an infectious microorganism
Yen et al. Cellular proteins specifically bind to the 5′-noncoding region of hepatitis C virus RNA
WO1996038474A3 (en) Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide
ES2143996T5 (en) PEPTIDIC ANTIGENS OF HCV AND PROCEDURE FOR THE DETERMINATION OF HCV.
EP1806363A4 (en) METHOD FOR DETECTION OF ANTIGEN S OF HEPATITIS B VIRUS
EP1878797A3 (en) Antigenic peptides for grouping hepatitis c virus, kit comprising the same and methods for its grouping using the same
MY116208A (en) Improved hcv diagnostic agents
CA2495456C (en) Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof
FR2690921A1 (en) Synthetic polypeptides belonging to the hepatitis C virus (HCV) and usable in particular for detecting the latter.
DE69106141D1 (en) NON-A NON-B SEQUENCES.
JP2005510211A5 (en)
US5885771A (en) Antigenic peptide compound and immunoassay
IE922548A1 (en) Non-a, non-b peptide
FR2794864A1 (en) METHOD OF EARLY DETECTION OF FLAVIVIRUSES AND ITS APPLICATIONS
TW369600B (en) Antigenic peptides for grouping hepatitis C virus, kit comprising the same and methods for its grouping the same
EP0672066A1 (en) Peptides from the c33 region of hcv, antibodies thereto and methods for the detection of hcv
KR19990044211A (en) Antigen Peptide Compounds and Immunological Measurement Methods
CA2151128A1 (en) Hepatitis c virus (hcv) non-structural-3 peptides, antibodies thereto and methods for the detection of hcv